[
 {
  "trial": "T055",
  "source": "fulltext",
  "arms": {
   "S group": {
    "randomized": "75",
    "analysed": "66"
   },
   "C group": {
    "randomized": "75",
    "analysed": "63"
   }
  },
  "depression": [
   {
    "measure": "EPDS",
    "day": -1,
    "form": "mean_sd",
    "location": "Table 3 (EPDS score, Before operation)",
    "values": {
     "S group": {
      "mean": "4.12",
      "sd": "0.64",
      "n": "66"
     },
     "C group": {
      "mean": "4.08",
      "sd": "0.63",
      "n": "65"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 3,
    "form": "mean_sd",
    "location": "Table 3 (EPDS score, 3 days after surgery)",
    "values": {
     "S group": {
      "mean": "6.42",
      "sd": "0.75",
      "n": "66"
     },
     "C group": {
      "mean": "6.95",
      "sd": "0.58",
      "n": "65"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 3,
    "form": "count",
    "definition": "EPDS ≥ 10",
    "location": "Table 3 (Occurrence of postpartum depression, 3 days after surgery)",
    "values": {
     "S group": {
      "events": "0",
      "n": "66",
      "definition": "EPDS ≥ 10"
     },
     "C group": {
      "events": "0",
      "n": "65",
      "definition": "EPDS ≥ 10"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 7,
    "form": "mean_sd",
    "location": "Table 3 (EPDS score, 7 days after surgery)",
    "values": {
     "S group": {
      "mean": "8.58",
      "sd": "0.88",
      "n": "66"
     },
     "C group": {
      "mean": "9.05",
      "sd": "0.63",
      "n": "65"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 7,
    "form": "count",
    "definition": "EPDS ≥ 10",
    "location": "Table 3 (Occurrence of postpartum depression, 7 days after surgery)",
    "values": {
     "S group": {
      "events": "8",
      "n": "66",
      "definition": "EPDS ≥ 10"
     },
     "C group": {
      "events": "8",
      "n": "65",
      "definition": "EPDS ≥ 10"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 14,
    "form": "mean_sd",
    "location": "Table 3 (EPDS score, 14 days after surgery)",
    "values": {
     "S group": {
      "mean": "5.86",
      "sd": "0.76",
      "n": "66"
     },
     "C group": {
      "mean": "6.21",
      "sd": "0.68",
      "n": "65"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 14,
    "form": "count",
    "definition": "EPDS ≥ 10",
    "location": "Table 3 (Occurrence of postpartum depression, 14 days after surgery)",
    "values": {
     "S group": {
      "events": "0",
      "n": "66",
      "definition": "EPDS ≥ 10"
     },
     "C group": {
      "events": "0",
      "n": "65",
      "definition": "EPDS ≥ 10"
     }
    }
   }
  ],
  "pain": [
   {
    "measure": "VAS at rest",
    "day": 1,
    "form": "mean_sd",
    "location": "Table 3 (T2 VAS score (static), 24 h)",
    "values": {
     "S group": {
      "mean": "3.50",
      "sd": "0.50",
      "n": "66"
     },
     "C group": {
      "mean": "4.17",
      "sd": "0.38",
      "n": "65"
     }
    }
   },
   {
    "measure": "VAS at rest",
    "day": 2,
    "form": "mean_sd",
    "location": "Table 3 (T3 VAS score (static), 48 h)",
    "values": {
     "S group": {
      "mean": "2.00",
      "sd": "0.00",
      "n": "66"
     },
     "C group": {
      "mean": "2.06",
      "sd": "0.25",
      "n": "65"
     }
    }
   },
   {
    "measure": "VAS on movement",
    "day": 1,
    "form": "mean_sd",
    "location": "Table 3 (T2 VAS score (move), 24 h)",
    "values": {
     "S group": {
      "mean": "4.50",
      "sd": "0.54",
      "n": "66"
     },
     "C group": {
      "mean": "5.17",
      "sd": "0.38",
      "n": "65"
     }
    }
   },
   {
    "measure": "VAS on movement",
    "day": 2,
    "form": "mean_sd",
    "location": "Table 3 (T3 VAS score (move), 48 h)",
    "values": {
     "S group": {
      "mean": "3.00",
      "sd": "0.00",
      "n": "66"
     },
     "C group": {
      "mean": "3.06",
      "sd": "0.25",
      "n": "65"
     }
    }
   },
   {
    "measure": "effective PCIA presses at 48 h",
    "day": 2,
    "form": "mean_sd",
    "location": "Table 3 (Total number of PCIA compressions in 48 hours)",
    "values": {
     "S group": {
      "mean": "7.58",
      "sd": "1.50",
      "n": "66"
     },
     "C group": {
      "mean": "14.75",
      "sd": "1.78",
      "n": "65"
     }
    }
   }
  ],
  "adverse_events": [
   {
    "window": "intraoperative",
    "time": "5 min after administration",
    "location": "Table 2",
    "n": {
     "S group": "66",
     "C group": "63"
    },
    "terms": {
     "visual": "Nystagmus",
     "dizziness": "Dizziness",
     "hallucination": "Hallucinations"
    },
    "values": {
     "S group": {
      "visual": "65",
      "dizziness": "63",
      "hallucination": "25"
     },
     "C group": {
      "visual": "0",
      "dizziness": "0",
      "hallucination": "0"
     }
    }
   },
   {
    "window": "intraoperative",
    "time": "15 min after administration",
    "location": "Table 2",
    "n": {
     "S group": "66",
     "C group": "63"
    },
    "terms": {
     "visual": "Nystagmus",
     "dizziness": "Dizziness",
     "hallucination": "Hallucinations"
    },
    "values": {
     "S group": {
      "visual": "4",
      "dizziness": "6",
      "hallucination": "8"
     },
     "C group": {
      "visual": "0",
      "dizziness": "0",
      "hallucination": "0"
     }
    }
   },
   {
    "window": "postoperative",
    "time": "on leaving the operating room",
    "location": "Table 2",
    "n": {
     "S group": "66",
     "C group": "63"
    },
    "terms": {
     "visual": "Diplopia",
     "dizziness": "Dizziness",
     "hallucination": "Hallucinations"
    },
    "values": {
     "S group": {
      "visual": "1",
      "dizziness": "1",
      "hallucination": "0"
     },
     "C group": {
      "visual": "0",
      "dizziness": "0",
      "hallucination": "0"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": {
   "start": "2024-02-16",
   "end": "2024-04-30"
  },
  "registration": {
   "number": "ChiCTR2400080884",
   "date": "2024-02-15"
  },
  "note": "Arm sizes: 75 randomized per group; 2 S and 4 C were excluded for blood loss > 500 mL and 7 S and 8 C were lost to follow-up, leaving 66 and 63 (129 analysed), as in Table 1 (N) and Table 2 (n). Table 3, the outcome table, heads the C column n = 65; the outcome entries copy Table 3's printed n (66 and 65), while 'analysed' is 63. Printed C figures are mixed: Table 3's PPD at day 7, 8 (12.7%), and adjuvant analgesia, 19 (30.2%), fit 63, while Table 2's visceral traction pain, 39 (60.0%), and Table 1's ASA II row, 65 (100%), fit 65. EPDS is in Table 3 both as mean ± SD and as 'Occurrence of postpartum depression' at 3, 7, and 14 days, which Methods 2.6 define as EPDS ≥ 10. Pain: VAS was measured at 4 h (T1, outside the day windows, left out), 24 h (T2, day 1), and 48 h (T3, day 2); 'static' is at rest and 'move' on movement. 'Postoperative adjuvant analgesia' (S 2 (3.00%), C 19 (30.2%)) is not a design measure and has no time, so it is left out. Adverse events are Table 2's counts at 5 and 15 min after the study drug (given within 10 min of cord clamping, so intraoperative) and on leaving the operating room (postoperative), one entry per time ('time'). Table 2 prints nystagmus and diplopia as separate rows (S nystagmus 65, 4, 0 and diplopia 7, 1, 1 at 5 min, 15 min, and leaving the operating room; C 0 throughout); 'visual' is the larger of the two at each time ('terms' names the row), since participants with both can't be told apart and the sum would exceed the arm at 5 min. S dizziness and diplopia on leaving the operating room print as '1 (0%)'; the count is copied. The Results text also names blurred vision as more frequent at 5 min, with no count. Drowsiness, lacrimation, nausea, vomiting, Ramsay > 3, and visceral traction pain are not codebook categories. Enrollment dates are from Methods 2.2 (the Results don't restate them); registered on 15 February 2024, the day before enrollment began.",
  "reason": "The coders agreed on every number and differed in two ways. The count entries' definition: A put 'EPDS ≥ 10' in each arm's values and B at the entry level; the codebook lists definition with each arm's count values, so it is kept there (and at the entry level too), and Table 3's 'Occurrence of postpartum depression' rows and Methods 2.6 confirm the counts and the cut-off. Visual adverse events: Table 2 prints nystagmus and diplopia as separate rows, which B coded as two 'visual' entries per time and A as the larger of the two; the codebook wants one count of participants with visual symptoms per arm and time, and the rows overlap (65 + 7 exceeds the 66 in the arm at 5 min), so A's larger printed count is kept (65, 4, and 1), with both rows' numbers in the note."
 },
 {
  "trial": "T124",
  "source": "preprint",
  "arms": {
   "Group T (esketamine)": {
    "randomized": null,
    "analysed": "40"
   },
   "Group C (saline)": {
    "randomized": null,
    "analysed": "40"
   }
  },
  "depression": [
   {
    "measure": "EPDS",
    "day": -1,
    "form": "mean_sd",
    "location": "Table 4 (EPDS scores, Preoperative Day)",
    "values": {
     "Group T (esketamine)": {
      "mean": "3.4",
      "sd": "1.8",
      "n": "40"
     },
     "Group C (saline)": {
      "mean": "3.8",
      "sd": "1.8",
      "n": "40"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 7,
    "form": "mean_sd",
    "location": "Table 4 (EPDS scores, 1 week post-op)",
    "values": {
     "Group T (esketamine)": {
      "mean": "5.3",
      "sd": "2.7",
      "n": "40"
     },
     "Group C (saline)": {
      "mean": "6.5",
      "sd": "2.8",
      "n": "40"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 7,
    "form": "count",
    "definition": "EPDS ≥ 13",
    "location": "Table 4 (Incidence of PPD, 1 week post-op)",
    "values": {
     "Group T (esketamine)": {
      "events": "3",
      "n": "40",
      "definition": "EPDS ≥ 13"
     },
     "Group C (saline)": {
      "events": "10",
      "n": "40",
      "definition": "EPDS ≥ 13"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 42,
    "form": "mean_sd",
    "location": "Table 4 (EPDS scores, 6 weeks post-op)",
    "values": {
     "Group T (esketamine)": {
      "mean": "4.3",
      "sd": "2.8",
      "n": "40"
     },
     "Group C (saline)": {
      "mean": "5.6",
      "sd": "2.3",
      "n": "40"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 42,
    "form": "count",
    "definition": "EPDS ≥ 13",
    "location": "Table 4 (Incidence of PPD, 6 weeks post-op)",
    "values": {
     "Group T (esketamine)": {
      "events": "2",
      "n": "40",
      "definition": "EPDS ≥ 13"
     },
     "Group C (saline)": {
      "events": "8",
      "n": "40",
      "definition": "EPDS ≥ 13"
     }
    }
   }
  ],
  "pain": [
   {
    "measure": "NRS at rest",
    "day": 1,
    "form": "mean_sd",
    "location": "Table 2 (Rest NRS score, 24h post-op)",
    "values": {
     "Group T (esketamine)": {
      "mean": "2.5",
      "sd": "1.1",
      "n": "40"
     },
     "Group C (saline)": {
      "mean": "3.0",
      "sd": "1.3",
      "n": "40"
     }
    }
   },
   {
    "measure": "NRS at rest",
    "day": 2,
    "form": "mean_sd",
    "location": "Table 2 (Rest NRS score, 48h post-op)",
    "values": {
     "Group T (esketamine)": {
      "mean": "2.0",
      "sd": "1.2",
      "n": "40"
     },
     "Group C (saline)": {
      "mean": "2.5",
      "sd": "1.0",
      "n": "40"
     }
    }
   },
   {
    "measure": "dynamic NRS",
    "day": 1,
    "form": "mean_sd",
    "location": "Table 2 (Dynamic NRS score, 24h post-op)",
    "values": {
     "Group T (esketamine)": {
      "mean": "3.6",
      "sd": "1.1",
      "n": "40"
     },
     "Group C (saline)": {
      "mean": "4.2",
      "sd": "1.1",
      "n": "40"
     }
    }
   },
   {
    "measure": "dynamic NRS",
    "day": 2,
    "form": "mean_sd",
    "location": "Table 2 (Dynamic NRS score, 48h post-op)",
    "values": {
     "Group T (esketamine)": {
      "mean": "3.0",
      "sd": "1.2",
      "n": "40"
     },
     "Group C (saline)": {
      "mean": "3.6",
      "sd": "1.2",
      "n": "40"
     }
    }
   },
   {
    "measure": "uterine contraction pain NRS",
    "day": 1,
    "form": "mean_sd",
    "location": "Table 2 (Uterine contraction pain NRS score, 24h post-op)",
    "values": {
     "Group T (esketamine)": {
      "mean": "3.1",
      "sd": "1.1",
      "n": "40"
     },
     "Group C (saline)": {
      "mean": "3.7",
      "sd": "1.2",
      "n": "40"
     }
    }
   },
   {
    "measure": "uterine contraction pain NRS",
    "day": 2,
    "form": "mean_sd",
    "location": "Table 2 (Uterine contraction pain NRS score, 48h post-op)",
    "values": {
     "Group T (esketamine)": {
      "mean": "2.7",
      "sd": "1.2",
      "n": "40"
     },
     "Group C (saline)": {
      "mean": "3.3",
      "sd": "1.3",
      "n": "40"
     }
    }
   },
   {
    "measure": "PCIA bolus requests (tramadol)",
    "day": 2,
    "form": "mean_sd",
    "location": "Table 2 (Number of rescue analgesia requests, 48h post-op)",
    "values": {
     "Group T (esketamine)": {
      "mean": "1.9",
      "sd": "1.4",
      "n": "40"
     },
     "Group C (saline)": {
      "mean": "2.7",
      "sd": "1.4",
      "n": "40"
     }
    }
   }
  ],
  "adverse_events": [
   {
    "window": "postoperative",
    "location": "Table 5",
    "n": {
     "Group T (esketamine)": "40",
     "Group C (saline)": "40"
    },
    "terms": {
     "dizziness": "Dizziness",
     "agitation": "Agitation/excitement",
     "any_ae": "Overall incidence of adverse events"
    },
    "values": {
     "Group T (esketamine)": {
      "dizziness": "3",
      "agitation": "1",
      "any_ae": "19"
     },
     "Group C (saline)": {
      "dizziness": "2",
      "agitation": "0",
      "any_ae": "16"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": {
   "start": "2024-10",
   "end": "2025-05"
  },
  "registration": {
   "number": "ChiCTR2400090341",
   "date": "2024-09-27"
  },
  "note": "Randomized per arm is not printed in the Results: 84 were randomized, 2 per group were converted to general anaesthesia and excluded, none was lost to follow-up, and 40 per group were analysed (all tables n = 40). The abstract instead says 80 were randomized, 40 per group, and Methods planned 44 per group (88 enrolled, 4 refused). Table 2's last row is labelled 'Number of rescue analgesia requests' (48 h only), but the Results text calls the same Table 2 result the number of PCIA bolus requests within 48 hours, so it is recorded under the design's PCIA measure; no 24 h value is given. Rest NRS at 2, 6, and 12 h is outside the day windows and left out. EPDS positive screen is EPDS ≥ 13 (Methods); the Results text's percentages (7.5% vs 25.0% at 1 week, 5.0% vs 20.0% at 6 weeks) match Table 4. Adverse events are Table 5's postoperative adverse reactions ('Agitation/excitement' recorded as agitation; 'Overall incidence of adverse events' as any_ae); nausea and vomiting (8 vs 8), pruritus (4 vs 3), shivering (4 vs 5), and somnolence (2 vs 1), Group T vs Group C, are not codebook categories. The abstract names blurred vision and irritability as slightly more frequent in Group T but gives no counts, and the Discussion says 'no severe adverse events including hallucinations, severe agitation or consciousness disturbance were recorded' (no count printed, so no hallucination zero is recorded). Enrollment dates are from Methods (October 2024 to May 2025). Registration date 27/09/2024 is from the abstract and Declarations, which call it retrospective, while Methods say it was registered before enrollment.",
  "reason": "The only difference was where the count entries' definition sits: A in each arm's values, B at the entry level. The codebook lists definition with each arm's count values, so it is kept there (and at the entry level too). Table 4's 'Incidence of PPD' rows (Group T 3 (7.5%) vs Group C 10 (25.0%) at 1 week, 2 (5.0%) vs 8 (20.0%) at 6 weeks, n = 40 each) and the Methods' positive screen, EPDS ≥ 13, match both coders; every other value agreed and checks against Tables 2, 4, and 5."
 },
 {
  "trial": "T125",
  "source": "preprint",
  "arms": {
   "Esketamine group": {
    "randomized": "62",
    "analysed": "60"
   },
   "Control group": {
    "randomized": "62",
    "analysed": "61"
   }
  },
  "depression": [
   {
    "measure": "EPDS",
    "day": -1,
    "form": "median_iqr",
    "location": "Table 3 (EPDS, Preoperative)",
    "values": {
     "Esketamine group": {
      "median": "4.0",
      "q1": "2.0",
      "q3": "4.0",
      "n": "60"
     },
     "Control group": {
      "median": "4.0",
      "q1": "3.0",
      "q3": "4.0",
      "n": "61"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 1,
    "form": "median_iqr",
    "location": "Table 3 (EPDS, 24 h)",
    "values": {
     "Esketamine group": {
      "median": "8.0",
      "q1": "6.0",
      "q3": "9.0",
      "n": "60"
     },
     "Control group": {
      "median": "9.0",
      "q1": "8.0",
      "q3": "10.0",
      "n": "61"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 3,
    "form": "median_iqr",
    "location": "Table 3 (EPDS, 72 h)",
    "values": {
     "Esketamine group": {
      "median": "3.0",
      "q1": "3.0",
      "q3": "4.0",
      "n": "60"
     },
     "Control group": {
      "median": "6.0",
      "q1": "5.0",
      "q3": "6.0",
      "n": "61"
     }
    }
   }
  ],
  "pain": [
   {
    "measure": "VAS at rest",
    "day": 1,
    "form": "median_iqr",
    "location": "Table 2 (Resting VAS, 24 h)",
    "values": {
     "Esketamine group": {
      "median": "2.0",
      "q1": "2.0",
      "q3": "2.0",
      "n": "60"
     },
     "Control group": {
      "median": "2.0",
      "q1": "2.0",
      "q3": "2.0",
      "n": "61"
     }
    }
   },
   {
    "measure": "VAS at rest",
    "day": 2,
    "form": "median_iqr",
    "location": "Table 2 (Resting VAS, 48 h)",
    "values": {
     "Esketamine group": {
      "median": "3.0",
      "q1": "2.0",
      "q3": "3.0",
      "n": "60"
     },
     "Control group": {
      "median": "3.0",
      "q1": "3.0",
      "q3": "3.0",
      "n": "61"
     }
    }
   },
   {
    "measure": "movement-evoked VAS",
    "day": 1,
    "form": "median_iqr",
    "location": "Table 2 (Movement-evoked VAS, 24 h)",
    "values": {
     "Esketamine group": {
      "median": "4.0",
      "q1": "3.0",
      "q3": "4.0",
      "n": "60"
     },
     "Control group": {
      "median": "5.0",
      "q1": "4.0",
      "q3": "5.0",
      "n": "61"
     }
    }
   },
   {
    "measure": "movement-evoked VAS",
    "day": 2,
    "form": "median_iqr",
    "location": "Table 2 (Movement-evoked VAS, 48 h)",
    "values": {
     "Esketamine group": {
      "median": "4.0",
      "q1": "3.0",
      "q3": "5.0",
      "n": "60"
     },
     "Control group": {
      "median": "5.0",
      "q1": "4.0",
      "q3": "5.0",
      "n": "61"
     }
    }
   },
   {
    "measure": "effective PCA presses",
    "day": 1,
    "form": "median_iqr",
    "location": "Table 2 (Effective PCA presses (n), 24 h)",
    "values": {
     "Esketamine group": {
      "median": "3.0",
      "q1": "2.0",
      "q3": "3.0",
      "n": "60"
     },
     "Control group": {
      "median": "3.0",
      "q1": "3.0",
      "q3": "4.0",
      "n": "61"
     }
    }
   },
   {
    "measure": "effective PCA presses",
    "day": 2,
    "form": "median_iqr",
    "location": "Table 2 (Effective PCA presses (n), 48 h)",
    "values": {
     "Esketamine group": {
      "median": "3.0",
      "q1": "3.0",
      "q3": "4.0",
      "n": "60"
     },
     "Control group": {
      "median": "4.0",
      "q1": "3.0",
      "q3": "5.0",
      "n": "61"
     }
    }
   },
   {
    "measure": "rescue butorphanol within 24 h",
    "day": 1,
    "form": "count",
    "definition": "rescue analgesia (IV butorphanol 1 mg for VAS > 5) within 24 h",
    "location": "Table 2 (24-h rescue analgesia, n (%))",
    "values": {
     "Esketamine group": {
      "events": "6",
      "n": "60",
      "definition": "rescue analgesia (IV butorphanol 1 mg for VAS > 5) within 24 h"
     },
     "Control group": {
      "events": "15",
      "n": "61",
      "definition": "rescue analgesia (IV butorphanol 1 mg for VAS > 5) within 24 h"
     }
    }
   }
  ],
  "adverse_events": [
   {
    "window": "overall",
    "location": "Table 5; Results, Adverse events",
    "n": {
     "Esketamine group": "60",
     "Control group": "61"
    },
    "terms": {
     "dizziness": "Dizziness",
     "hallucination": "Hallucinations / nightmares",
     "nightmare": "Hallucinations / nightmares",
     "any_ae": "Total"
    },
    "values": {
     "Esketamine group": {
      "dizziness": "1",
      "hallucination": "0",
      "nightmare": "0",
      "any_ae": "4"
     },
     "Control group": {
      "dizziness": "2",
      "hallucination": "0",
      "nightmare": "0",
      "any_ae": "6"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": {
   "start": "2025-04",
   "end": "2025-12"
  },
  "registration": {
   "number": "ChiCTR2500099435",
   "date": null
  },
  "note": "Randomized 62 per group; withdrawn after randomization: 1 control (conversion to general anaesthesia) and 2 esketamine (intraoperative hemorrhage, intrauterine balloon), leaving 60 and 61 in every table. The text after the Results repeats the full preprint (abstract, methods, results, discussion) with the same numbers. EPDS was measured preoperatively and at 24 and 72 h (Table 3, median (P25, P75)); follow-up ended at 72 h, so no PPD incidence. Per-time n is the table header (missing data < 5%, available-case analysis). Pain: VAS at 2 and 6 h and PCA presses at 6 and 12 h are outside the day windows and left out; Table 2 doesn't say whether PCA presses at each time are cumulative. Rescue analgesia within 24 h: RD −14.6% (−27.8%, −1.4%) also printed. Adverse events (Table 5): the assessment window is not stated, so 'overall'; 'Hallucinations / nightmares' is one row (0 (0.0) in both arms, and the text says neither group had hallucinations or nightmares), recorded as hallucination 0 and nightmare 0; 'Total' recorded as any_ae; nausea and vomiting (3 vs 5), pruritus (0 vs 0), and respiratory depression (0 vs 0), esketamine vs control, are not codebook categories. Enrollment April to December 2025 is from the Results (Methods add that the last participant was assessed on December 2, 2025). Registered retrospectively; no registration date given.",
  "reason": "The only difference was where the 24-h rescue analgesia count's definition sits (A in each arm's values, B at the entry level). The codebook lists definition with each arm's count values, so it is kept there (and at the entry level too), worded from the Methods (IV butorphanol 1 mg for VAS > 5) and Table 2's '24-h rescue analgesia' row (6 (10.0) vs 15 (24.6), n = 60 and 61). All other values agreed and match Tables 2, 3, and 5."
 },
 {
  "trial": "T106",
  "source": "fulltext",
  "arms": {
   "Esketamine group": {
    "randomized": "50",
    "analysed": "50"
   },
   "Control group": {
    "randomized": "50",
    "analysed": "50"
   }
  },
  "depression": [],
  "pain": [
   {
    "measure": "VAS at rest",
    "day": 1,
    "form": "median_iqr",
    "location": "Table 3 (VAS scores at rest, Postoperative day 1)",
    "values": {
     "Esketamine group": {
      "median": "3",
      "q1": "3",
      "q3": "3",
      "n": "50"
     },
     "Control group": {
      "median": "3.5",
      "q1": "3",
      "q3": "4",
      "n": "50"
     }
    }
   },
   {
    "measure": "VAS during movement (coughing/deep breathing)",
    "day": 1,
    "form": "median_iqr",
    "location": "Table 3 (VAS scores for movement, Postoperative day 1)",
    "values": {
     "Esketamine group": {
      "median": "3",
      "q1": "3",
      "q3": "4",
      "n": "50"
     },
     "Control group": {
      "median": "4",
      "q1": "3",
      "q3": "4",
      "n": "50"
     }
    }
   },
   {
    "measure": "hydromorphone intake",
    "day": 1,
    "form": "median_iqr",
    "location": "Table 3 (Consumption of hydromorphone after surgery (mg), 24 h after surgery)",
    "values": {
     "Esketamine group": {
      "median": "5",
      "q1": "4",
      "q3": "5",
      "n": "50"
     },
     "Control group": {
      "median": "5",
      "q1": "4.5",
      "q3": "5",
      "n": "50"
     }
    }
   },
   {
    "measure": "hydromorphone intake",
    "day": 2,
    "form": "median_iqr",
    "location": "Table 3 (Consumption of hydromorphone after surgery (mg), 48 h after surgery)",
    "values": {
     "Esketamine group": {
      "median": "9",
      "q1": "8.5",
      "q3": "9.5",
      "n": "50"
     },
     "Control group": {
      "median": "9",
      "q1": "8.5",
      "q3": "10",
      "n": "50"
     }
    }
   }
  ],
  "adverse_events": [
   {
    "window": "postoperative",
    "location": "Table 3 (Postoperative adverse events, n (%))",
    "n": {
     "Esketamine group": "50",
     "Control group": "50"
    },
    "values": {
     "Esketamine group": {
      "dizziness": "1",
      "nightmare": "0"
     },
     "Control group": {
      "dizziness": "2",
      "nightmare": "0"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": null,
  "registration": {
   "number": "ChiCTR2500096036",
   "date": null
  },
  "note": "The source calls the arms 'Experimental' (esketamine) and 'Control'; Figure 1's caption says 100 randomized, 50 per arm, none lost, all analysed. HADS-D (with HADS-A) on preoperative day 1 and postoperative days 1, 3, and 5 appears only in Figure 4 (median with IQR) with no printed values, so depression is empty. Table 3's 'median (quartile)' values (Methods) are recorded as median_iqr. Experimental VAS during movement on postoperative day 1 is printed '3 (3.4)', read as 3 (3,4), the period taken for the table's comma; the 'VAS scores for movement' heading row also carries a stray '3 (3,3)' in the Experimental column. The Results text cites Table 2 for VAS, but the values are in Table 3 (Table 2's 'NRS score' is a sleep NRS). VAS is not reported on postoperative day 2; VAS immediately after surgery and on postoperative days 3 and 5, and intraoperative opioid consumption, fall outside the day 1 and day 2 windows. Hydromorphone at 24 and 48 h after surgery is coded days 1 and 2. Postoperative delirium (Control 5 (10), Experimental 7 (14)) is not mapped: it is undefined and not described as excitement on emergence, which is what the codebook puts under agitation. Pruritis (0 and 0) and nausea and vomiting (7 vs 5, Control vs Experimental) are not codebook categories. No enrollment dates or registration date given.",
  "reason": "The only difference was postoperative delirium (Experimental 7, Control 5, Table 3), which B coded as agitation and A left out. The codebook's agitation takes in delirium-like excitement on emergence; this is an undefined postoperative delirium count with nothing saying it was emergence excitement (postoperative delirium can be hypoactive), so it fits no category and is left out, with its counts in the note. Everything else agreed and checks against Table 3."
 },
 {
  "trial": "T112",
  "source": "fulltext",
  "arms": {
   "Esketamine": {
    "randomized": "218",
    "analysed": "207"
   },
   "Placebo (normal saline)": {
    "randomized": "217",
    "analysed": "203"
   }
  },
  "depression": [
   {
    "measure": "MADRS (remission <=10 at POD 3 primary; response; scores at POD 3 and 5)",
    "day": -1,
    "form": "median_iqr",
    "location": "Table 1 (Preoperative assessment, MADRS, median (IQR))",
    "values": {
     "Esketamine": {
      "median": "24",
      "q1": "23",
      "q3": "27",
      "n": "218"
     },
     "Placebo (normal saline)": {
      "median": "24",
      "q1": "22",
      "q3": "27",
      "n": "217"
     }
    }
   },
   {
    "measure": "MADRS (remission <=10 at POD 3 primary; response; scores at POD 3 and 5)",
    "day": -1,
    "form": "count",
    "definition": "severe depressive symptoms, MADRS ≥ 30",
    "location": "Table 1 (Severe depressive symptoms, n (%)); Results 3.1 (22/218, 22/217)",
    "values": {
     "Esketamine": {
      "events": "22",
      "n": "218",
      "definition": "severe depressive symptoms, MADRS ≥ 30"
     },
     "Placebo (normal saline)": {
      "events": "22",
      "n": "217",
      "definition": "severe depressive symptoms, MADRS ≥ 30"
     }
    }
   },
   {
    "measure": "MADRS (remission <=10 at POD 3 primary; response; scores at POD 3 and 5)",
    "day": 3,
    "form": "median_iqr",
    "location": "Table 2, Assessments on POD3 (MADRS score, median (IQR))",
    "values": {
     "Esketamine": {
      "median": "15",
      "q1": "10",
      "q3": "20",
      "n": "207"
     },
     "Placebo (normal saline)": {
      "median": "18",
      "q1": "15",
      "q3": "22",
      "n": "203"
     }
    }
   },
   {
    "measure": "MADRS (remission <=10 at POD 3 primary; response; scores at POD 3 and 5)",
    "day": 3,
    "form": "count",
    "definition": "remission, MADRS ≤ 10 (events are participants in remission, not with depression)",
    "location": "Table 2, Primary Outcome (Remission on day 3, No./total (%))",
    "values": {
     "Esketamine": {
      "events": "59",
      "n": "207",
      "definition": "remission, MADRS ≤ 10 (events are participants in remission, not with depression)"
     },
     "Placebo (normal saline)": {
      "events": "23",
      "n": "203",
      "definition": "remission, MADRS ≤ 10 (events are participants in remission, not with depression)"
     }
    }
   },
   {
    "measure": "MADRS (remission <=10 at POD 3 primary; response; scores at POD 3 and 5)",
    "day": 3,
    "form": "count",
    "definition": "response, MADRS reduction ≥ half of baseline (events are responders, not participants with depression)",
    "location": "Table 2, Assessments on POD3 (Response, No./total (%))",
    "values": {
     "Esketamine": {
      "events": "89",
      "n": "207",
      "definition": "response, MADRS reduction ≥ half of baseline (events are responders, not participants with depression)"
     },
     "Placebo (normal saline)": {
      "events": "35",
      "n": "203",
      "definition": "response, MADRS reduction ≥ half of baseline (events are responders, not participants with depression)"
     }
    }
   },
   {
    "measure": "MADRS (remission <=10 at POD 3 primary; response; scores at POD 3 and 5)",
    "day": 5,
    "form": "median_iqr",
    "location": "Table 2, Assessments on discharge (MADRS score, median (IQR))",
    "values": {
     "Esketamine": {
      "median": "14",
      "q1": "10",
      "q3": "19",
      "n": "198"
     },
     "Placebo (normal saline)": {
      "median": "17",
      "q1": "13",
      "q3": "21",
      "n": "201"
     }
    }
   },
   {
    "measure": "MADRS (remission <=10 at POD 3 primary; response; scores at POD 3 and 5)",
    "day": 5,
    "form": "count",
    "definition": "remission, MADRS ≤ 10 (events are participants in remission, not with depression)",
    "location": "Table 2, Assessments on discharge (Remission, No./total (%))",
    "values": {
     "Esketamine": {
      "events": "62",
      "n": "198",
      "definition": "remission, MADRS ≤ 10 (events are participants in remission, not with depression)"
     },
     "Placebo (normal saline)": {
      "events": "30",
      "n": "201",
      "definition": "remission, MADRS ≤ 10 (events are participants in remission, not with depression)"
     }
    }
   },
   {
    "measure": "MADRS (remission <=10 at POD 3 primary; response; scores at POD 3 and 5)",
    "day": 5,
    "form": "count",
    "definition": "response, MADRS reduction ≥ half of baseline (events are responders, not participants with depression)",
    "location": "Table 2, Assessments on discharge (Response, No./total (%))",
    "values": {
     "Esketamine": {
      "events": "86",
      "n": "198",
      "definition": "response, MADRS reduction ≥ half of baseline (events are responders, not participants with depression)"
     },
     "Placebo (normal saline)": {
      "events": "47",
      "n": "201",
      "definition": "response, MADRS reduction ≥ half of baseline (events are responders, not participants with depression)"
     }
    }
   }
  ],
  "pain": [
   {
    "measure": "Moderate-to-severe pain (any NRS >=4 within 72 h)",
    "day": 2,
    "form": "count",
    "definition": "NRS pain score > 3, 0–48 h",
    "location": "Table 2, Secondary Outcomes (NRS pain score > 3, 0–48 h, n (%))",
    "values": {
     "Esketamine": {
      "events": "50",
      "n": "218",
      "definition": "NRS pain score > 3, 0–48 h"
     },
     "Placebo (normal saline)": {
      "events": "47",
      "n": "217",
      "definition": "NRS pain score > 3, 0–48 h"
     }
    }
   }
  ],
  "adverse_events": [
   {
    "window": "postoperative",
    "time": "first 72 h after surgery (assessed at 4 h, 1 day, and 3 days after anesthesia)",
    "location": "Table 2, Adverse events (Dissociative symptoms, CADSS score ≥ 5); Results 3.4",
    "n": {
     "Esketamine": "218",
     "Placebo (normal saline)": "217"
    },
    "terms": {
     "dissociation": "Dissociative symptoms (CADSS score≥5)"
    },
    "values": {
     "Esketamine": {
      "dissociation": "19"
     },
     "Placebo (normal saline)": {
      "dissociation": "4"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": {
   "start": "2021-02",
   "end": "2024-06"
  },
  "registration": {
   "number": "NCT04425473",
   "date": "2020-06-11"
  },
  "note": "Randomized 218 and 217; 25 were lost to follow-up (aphasia or other conditions), so 'analysed' is the day-3 denominators, 207 and 203; discharge assessments have 198 and 201, and Table 2's header (218, 217) is the n for the pain and adverse-event rows. 'Assessments on discharge' are coded day 5: Methods plan MADRS at 3 and 5 days and bedside follow-up 'on days 1, 2, 3, and 5 or at discharge', but median hospital stay was 11 (9−14) vs 12 (9−15) days, so the timing is uncertain. MADRS score n at POD3 and at discharge are the MADRS remission and response denominators in the same section. Remission (MADRS ≤ 10) and response (MADRS reduction ≥ half of baseline) counts are participants who improved, not participants with depression; their definitions say so. The baseline count is Table 1's 'Severe depressive symptoms' (MADRS ≥ 30, Methods 2.4 and Fig. 3). The text gives day-3 remission as 28.3% (59/207); Table 2 prints 59/207 (28.5); the table's is taken. The text's day-3 MADRS IQR is garbled ('15 [10], [11], ... [20]'); the table's 15 (10–20) is taken. Pain: the design's measure (any NRS ≥ 4 within 72 h) is printed as 'NRS pain score > 3, 0–48 h' and coded day 2. Not extracted because the design doesn't list them (esketamine vs placebo): PHQ-9 at baseline 12 (11–14) vs 12 (10–13), PHQ-9 ≥ 10 52/207 vs 81/203 on POD3 and 44/198 vs 57/201 at discharge; HADS (defined as HADS-Depression, though baseline values above 21 suggest the total scale) 22 (18–25) vs 21 (17–24) at baseline, 16 (11–21) vs 20 (16–22) on POD3, and 17 (11–21) vs 19 (15–22) at discharge; GAD-7; and rescue analgesia, 0–48 h, 58 (26.6) vs 59 (27.2). Adverse events are Table 2's, assessed during the first 72 h: dissociative symptoms (CADSS ≥ 5) as dissociation. Not mapped to a category: psychotic side effects (4-item BPRS ≥ 5: unusual thought content, suspiciousness, hallucinations, conceptual disorganization) 23 vs 25, manic symptoms (YMRS ≥ 5) 14 vs 11, delirium 4 vs 11, and PONV 0–48 h 46 vs 50. Enrollment is the Methods' screening window (major surgery 'between February 19, 2021, and June 20, 2024'). The trial stopped at a prespecified interim analysis (435 of 564 planned).",
  "reason": "Adverse events: B coded the 4-item BPRS 'psychotic side effects' (23 vs 25) as psychiatric_any and delirium (4 vs 11) as agitation; A left both out, and A is kept. psychiatric_any is for a source that gives only a combined psychiatric count, while this one reports dissociation (CADSS ≥ 5) separately, so a BPRS-defined psychotic-symptom count isn't 'any psychiatric event'; and an undefined postoperative delirium isn't the emergence excitement the codebook puts under agitation. The other differences, HADS's n (B 207/203 and 198/201, A none) and the rescue-analgesia measure's name (hyphen vs the source's en dash), sit on measures the design doesn't list; the codebook extracts only the design's measures, so the HADS, PHQ-9, and rescue-analgesia entries are dropped, their printed values kept in the note. The MADRS and pain values both coders gave match Tables 1 and 2."
 }
]